Evidence map›Paper›PMID 39335192›Full record

ArticleCancers2024

Low-Risk and High-Risk NSMPs: A Prognostic Subclassification of No Specific Molecular Profile Subtype of Endometrial Carcinomas.

Matteo Marchetti, Giulia Spagnol, Tommaso Vezzaro, Sofia Bigardi, Orazio De Tommasi, Emma Facchetti, Marta Tripepi, Diletta Costeniero, Chiara Munerol, Tiziano Maggino and 4 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matteo MarchettiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0003-4427-0101
Giulia SpagnolUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0003-3525-0571
Tommaso VezzaroUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Sofia BigardiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0009-0004-6873-5924
Orazio De TommasiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0001-5890-9792
Emma FacchettiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Marta TripepiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Diletta CostenieroUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Chiara MunerolUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Tiziano MagginoUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0002-5177-8205
Donato D'AntonaUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Roberto TozziUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0001-6123-1628
Carlo SaccardiUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.ORCID 0000-0001-7476-997X
Marco NoventaUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Endometrial carcinoma (EC) classified as no specific molecular profile (NSMP) represents a heterogeneous group with variable prognoses. This retrospective, single-center study aims to further stratify NSMP ECs to tailor treatment strategies and improve outcomes. (2) Methods: From 2020 to 2023, we collected data on 51 patients diagnosed with NSMP EC following the introduction of molecular profiling at our institution. Patients were retrospectively analyzed for estrogen receptor (ER) status, histotype, and grade to identify potential prognostic subgroups. (3) Results: Our analysis identified two distinct subgroups within NSMP EC: low-risk and high-risk, based on ER status, histotype, and grade. The low-risk NSMP group demonstrated significantly better survival outcomes compared to the high-risk group. With a median follow-up time of 16 moths (IQR 13.0-29.7), the disease-free survival (DFS) and overall survival (OS) for the low-risk group were 100%. For the high-risk group, the DFS and OS were 71.4% and 78.6%, respectively, which showed a statistically significantly difference (Log-Rank Mantel-Cox < 0.001). In the high-risk group, four patients experienced recurrence, and three of these patients died. (4) Conclusions: Stratifying NSMP EC into low-risk and high-risk categories based on ER status, histotype, and grade can lead to more accurate prognostic assessments. In time, it may require tailored adjuvant therapies and a personalized treatment.

Indexed as

endometrial cancerestrogen receptormolecular classificationno specific molecular profileNSMPprognosisrisk class

Identifiers

PMID39335192
PMCPMC11429616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.